PCM
TARA icon

Prelude Capital Management’s Protara Therapeutics TARA Stock Holding History

Prelude Capital Management’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$74.9K Buy
+19,613
New +$93.3K 0.01% 1143
2025
Q4 		– Sell
-21,516
Closed -$93.6K – 1547
2025
Q3 		$93.6K Sell
21,516
-1,300
-6% -$4.21K 0.01% 1062
2025
Q2 		$69.1K Buy
+22,816
New +$78.7K 0.01% 944
2022
Q2 		– Sell
-12,872
Closed -$66K – 2052
2022
Q1 		$66K Sell
12,872
-3,983
-24% -$20.9K ﹤0.01% 1469
2021
Q4 		$114K Buy
16,855
+3,700
+28% +$25.5K ﹤0.01% 1690
2021
Q3 		$91K Buy
13,155
+1,455
+12% +$11.3K ﹤0.01% 1516
2021
Q2 		$114K Buy
+11,700
New +$133K ﹤0.01% 1448
2018
Q1 		– Sell
-124
Closed -$9K – 1713
2017
Q4 		$9K Buy
+124
New +$9.94K ﹤0.01% 1218

Other funds holding TARA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

Prelude Capital Management's TARA Position: Q2 2026 in Review

Prelude Capital Management opened a new position in Protara Therapeutics (TARA) in Q2 2026: 19,613 shares worth $74.9K. The stake represents 0.01% of the portfolio and ranks #1143 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in TARA as recently as Q3 2025.

Prelude Capital Management first reported a position in TARA in Q4 2017 and has held it in 8 quarters since. The position peaked at $114K in Q4 2021. 119 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

  • Prelude Capital Management held 19,613 shares of Protara Therapeutics worth $74.9K as of Q2 2026.
  • Protara Therapeutics was a new Prelude Capital Management position in Q2 2026.
  • Protara Therapeutics made up 0.01% of Prelude Capital Management's portfolio in Q2 2026, its #1143 holding.
  • Prelude Capital Management first reported a position in Protara Therapeutics in Q4 2017 and has held it in 8 quarters since.
  • Prelude Capital Management's Protara Therapeutics position peaked at $114K in Q4 2021.
  • 119 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.